Actualités NexGel Inc - NXGL | Actions NASDAQ

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Premium

NEXGEL to Present at Planet MicroCap Conference Las Vegas on June 16th –18th

LANGHORNE, Pa., June 04, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”...

NEXGEL Reports Positive Data from Randomized Single-Center IRB Study to Evaluate the Effectiveness and Safety of a Hydrogel Laser Treatment Patch in Laser Hair Removal with a 95.6% Reduction in Plume Concentration

The study concluded that NEXGEL’s hydrogel patch significantly reduced laser plume generation and exposure...

NEXGEL Appoints Dave Hazard as Vice President of Sales for BIONX Surgical

Appointment Supports Commercialization of Newly Launched BIONX Surgical Division, Formed Through Transformative...

NEXGEL Appoints Brian Kieser and Kevin Harris from New Strategic Partner, Sequence LifeScience™, to Board of Directors

Sequence LifeScienceTM Led Financing to Close on Acquisition of Celularity with Strategic Investment of $5.5...

NEXGEL Appoints Ian Blackman as Chief Financial Officer

Veteran Financial and M&A Leader Appointed to Integrate Acquisition of Celularity, Scale the Business and...

NEXGEL New Strategic Partner, Sequence LifeScience™, Leads Financing with $5.5 Million to Complete Acquisition of Celularity Degenerative Disease Segment

Transaction expected to approximately triple NEXGEL’s annual revenue to approximately $35 million and is...

NEXGEL Moves Forward Shareholder Update Call to Discuss Celularity Transaction on April 21st at 4:30 P.M. ET

LANGHORNE, Pa., April 17, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”...

NEXGEL Reschedules Shareholder Update Conference Call to April 23rd at 4:30 P.M. ET to Provide Update on Celularity Transaction

LANGHORNE, Pa., April 15, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”...

NEXGEL Reschedules Shareholder Update Conference Call to April 15th at 4:30 P.M. ET to Provide Update on Celularity Transaction

LANGHORNE, Pa., April 08, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”...

NEXGEL Reschedules 2025 Financial Results Conference Call to April 8th at 4:30 P.M. ET to Provide Shareholders with an Update on Its Previously Announced Transaction with Celularity

LANGHORNE, Pa., March 31, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”...

NEXGEL to Report Fourth Quarter and Full Year 2025 Financial Results on March 31st

Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa., March 25, 2026 (GLOBE...

NEXGEL Announces Consideration Terms of Agreement to License and Acquire Portfolio of Commercial-Stage Regenerative Biomaterial Products

Consideration for portfolio will consist of a $15 million upfront cash payment and potentially an additional...

Celularity Reiterates Strategic Commercialization Partnership with NEXGEL Focused on Building Biomaterials Franchise with Established Commercial Products and New 510(k) Pathway Product Opportunities

Biovance, Biovance 3L, Natalin, Acelagraft, Interfyl and Centaflex licensed to NEXGEL are established commercial products widely used today in...

NEXGEL Signs Definitive Agreement to License and Acquire Transformative Portfolio of Commercial-Stage Regenerative Biomaterial Products

Transaction expected to approximately triple NEXGEL’s annual revenue to about $35 million and is expected to...

NEXGEL Announces Financing of $1.797 Million Relating to an Acquisition Targeted to Close in the First Quarter of 2026, Subject to the Completion of Due Diligence

LANGHORNE, Pa., Feb. 10, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

NexGel Inc (NXGL)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

NexGel Inc (NXGL) Actualités

NEXGEL to Present at Planet MicroCap Conference Las Vegas on June 16th –18th

NEXGEL Reports Positive Data from Randomized Single-Center IRB Study to Evaluate the Effectiveness and Safety of a Hydrogel Laser Treatment Patch in Laser Hair Removal with a 95.6% Reduction in Plume Concentration

NEXGEL Appoints Dave Hazard as Vice President of Sales for BIONX Surgical

NEXGEL Appoints Brian Kieser and Kevin Harris from New Strategic Partner, Sequence LifeScience™, to Board of Directors

NEXGEL Appoints Ian Blackman as Chief Financial Officer

NEXGEL New Strategic Partner, Sequence LifeScience™, Leads Financing with $5.5 Million to Complete Acquisition of Celularity Degenerative Disease Segment

NEXGEL Moves Forward Shareholder Update Call to Discuss Celularity Transaction on April 21st at 4:30 P.M. ET

NEXGEL Reschedules Shareholder Update Conference Call to April 23rd at 4:30 P.M. ET to Provide Update on Celularity Transaction

NEXGEL Reschedules Shareholder Update Conference Call to April 15th at 4:30 P.M. ET to Provide Update on Celularity Transaction

NEXGEL Reschedules 2025 Financial Results Conference Call to April 8th at 4:30 P.M. ET to Provide Shareholders with an Update on Its Previously Announced Transaction with Celularity

NEXGEL to Report Fourth Quarter and Full Year 2025 Financial Results on March 31st

NEXGEL Announces Consideration Terms of Agreement to License and Acquire Portfolio of Commercial-Stage Regenerative Biomaterial Products

Celularity Reiterates Strategic Commercialization Partnership with NEXGEL Focused on Building Biomaterials Franchise with Established Commercial Products and New 510(k) Pathway Product Opportunities

NEXGEL Signs Definitive Agreement to License and Acquire Transformative Portfolio of Commercial-Stage Regenerative Biomaterial Products

NEXGEL Announces Financing of $1.797 Million Relating to an Acquisition Targeted to Close in the First Quarter of 2026, Subject to the Completion of Due Diligence

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

NexGel Inc (NXGL)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

NexGel Inc (NXGL) Actualités

NEXGEL to Present at Planet MicroCap Conference Las Vegas on June 16th –18th

NEXGEL Reports Positive Data from Randomized Single-Center IRB Study to Evaluate the Effectiveness and Safety of a Hydrogel Laser Treatment Patch in Laser Hair Removal with a 95.6% Reduction in Plume Concentration

NEXGEL Appoints Dave Hazard as Vice President of Sales for BIONX Surgical

NEXGEL Appoints Brian Kieser and Kevin Harris from New Strategic Partner, Sequence LifeScience™, to Board of Directors

NEXGEL Appoints Ian Blackman as Chief Financial Officer

NEXGEL New Strategic Partner, Sequence LifeScience™, Leads Financing with $5.5 Million to Complete Acquisition of Celularity Degenerative Disease Segment

NEXGEL Moves Forward Shareholder Update Call to Discuss Celularity Transaction on April 21st at 4:30 P.M. ET

NEXGEL Reschedules Shareholder Update Conference Call to April 23rd at 4:30 P.M. ET to Provide Update on Celularity Transaction

NEXGEL Reschedules Shareholder Update Conference Call to April 15th at 4:30 P.M. ET to Provide Update on Celularity Transaction

NEXGEL Reschedules 2025 Financial Results Conference Call to April 8th at 4:30 P.M. ET to Provide Shareholders with an Update on Its Previously Announced Transaction with Celularity

NEXGEL to Report Fourth Quarter and Full Year 2025 Financial Results on March 31st

NEXGEL Announces Consideration Terms of Agreement to License and Acquire Portfolio of Commercial-Stage Regenerative Biomaterial Products

Celularity Reiterates Strategic Commercialization Partnership with NEXGEL Focused on Building Biomaterials Franchise with Established Commercial Products and New 510(k) Pathway Product Opportunities

NEXGEL Signs Definitive Agreement to License and Acquire Transformative Portfolio of Commercial-Stage Regenerative Biomaterial Products

NEXGEL Announces Financing of $1.797 Million Relating to an Acquisition Targeted to Close in the First Quarter of 2026, Subject to the Completion of Due Diligence

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Pourquoi rejoindre ADVFN?

Tout ce dont les traders professionnels ont besoin.

Supprimer les publicités